Stay updated on Nivolumab for Stage IIB-IIC Melanoma Clinical Trial
Sign up to get notified when there's something new on the Nivolumab for Stage IIB-IIC Melanoma Clinical Trial page.

Latest updates to the Nivolumab for Stage IIB-IIC Melanoma Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoChange DetectedLocations section on the page was reorganized to list New Jersey, New York, and Pennsylvania as separate subsections, replacing the prior 'New Jersey Locations', 'New York Locations', and 'Pennsylvania Locations' headings. The HHS Vulnerability Disclosure link was removed from the footer and the page revision updated from v3.3.2 to v3.3.3.SummaryDifference0.5%

- Check19 days agoNo Change Detected
- Check26 days agoNo Change Detected
- Check33 days agoChange DetectedAdded an Outcome Measure: Number of Adverse Events and a new Last Update Posted (Estimated) field; removed the Incidence of adverse events and Last Update Posted fields.SummaryDifference0.4%

- Check41 days agoChange DetectedThe page now displays Revision: v3.3.2, replacing Revision: v3.2.0. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check48 days agoChange DetectedRemoved the government funding lapse notice from the page; the study details and eligibility information remain unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check62 days agoChange DetectedNo substantive changes to the trial's endpoints, eligibility criteria, or locations; the update appears cosmetic (e.g., timestamp) and does not affect the study details. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check91 days agoChange DetectedUpdated operating-status notice and version 3.2.0; removed version 3.1.0.SummaryDifference3%

Stay in the know with updates to Nivolumab for Stage IIB-IIC Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab for Stage IIB-IIC Melanoma Clinical Trial page.